Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate.
biochemical recurrence
intraductal carcinoma of the prostate
morphologic criteria
prostate cancer
prostate cancer prognosis
radical prostatectomy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Dec 2021
13 Dec 2021
Historique:
received:
30
10
2021
revised:
10
12
2021
accepted:
10
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Intraductal carcinoma of the prostate (IDC-P) is an aggressive subtype of prostate cancer strongly associated with an increased risk of biochemical recurrence (BCR). However, approximately 40% of men with IDC-P remain BCR-free five years after radical prostatectomy. In this retrospective multicenter study, we aimed to identify histologic criteria associated with BCR for IDC-P lesions. A total of 108 first-line radical prostatectomy specimens were reviewed. In our test cohort (
Identifiants
pubmed: 34944863
pii: cancers13246243
doi: 10.3390/cancers13246243
pmc: PMC8699439
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : CIHR
ID : CRP-154487
Pays : Canada
Organisme : Cancer Research Society
ID : CRP-154487
Organisme : Institut du cancer de Montréal
ID : N/A
Références
Prostate. 2018 Jan;78(1):11-16
pubmed: 29094384
Hum Pathol. 1998 Oct;29(10):1119-23
pubmed: 9781651
Eur Urol. 2017 Oct;72(4):492-495
pubmed: 28342640
Mod Pathol. 2018 Jan;31(S1):S71-79
pubmed: 29297491
Arch Pathol Lab Med. 2007 Jul;131(7):1103-9
pubmed: 17616999
Cancer. 1985 Oct 1;56(7):1566-73
pubmed: 4027893
Ann Diagn Pathol. 2014 Dec;18(6):333-42
pubmed: 25263387
Am J Clin Pathol. 2003 Dec;120 Suppl:S85-100
pubmed: 15298146
J Pathol. 2016 Jan;238(1):31-41
pubmed: 26331372
Eur Urol. 2017 Nov;72(5):665-674
pubmed: 28511883
Eur Urol. 2017 Nov;72(5):689-709
pubmed: 28189428
Am J Surg Pathol. 2018 Aug;42(8):1036-1041
pubmed: 29878934
Cancer. 1986 Oct 15;58(8):1714-9
pubmed: 3756794
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2518-26
pubmed: 24966964
Hum Pathol. 2001 Jan;32(1):81-8
pubmed: 11172299
Radiat Oncol. 2019 Apr 25;14(1):60
pubmed: 31018850
Pathol Res Pract. 2018 Oct;214(10):1681-1685
pubmed: 30195638
World J Urol. 2014 Jun;32(3):703-7
pubmed: 23887713
Am J Surg Pathol. 1996 Jul;20(7):802-14
pubmed: 8669528
Cancer Cell. 2013 Feb 11;23(2):159-70
pubmed: 23410972
J Clin Oncol. 2012 May 20;30(15):1857-63
pubmed: 22508816
Hum Pathol. 2014 Aug;45(8):1572-81
pubmed: 24842280
Cancer Prev Res (Phila). 2016 Aug;9(8):648-56
pubmed: 26813971
Histopathology. 2019 Jun;74(7):1081-1087
pubmed: 30720899
Mod Pathol. 2006 Dec;19(12):1528-35
pubmed: 16980940
Pathol Res Pract. 2017 Jun;213(6):612-618
pubmed: 28552539
Br J Urol. 1998 Mar;81(3):413-8
pubmed: 9523662
Am J Surg Pathol. 2010 Apr;34(4):470-7
pubmed: 20182345
Int J Cancer. 1984 Jan 15;33(1):37-42
pubmed: 6693192
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Rev Col Bras Cir. 2010 Oct;37(5):338-44
pubmed: 21180999
Prostate. 2000 Apr 1;43(1):11-9
pubmed: 10725861
Ann Diagn Pathol. 2011 Dec;15(6):414-21
pubmed: 21849255
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):59-66
pubmed: 17919840
PLoS Med. 2012;9(5):e1001216
pubmed: 22675273
Am J Surg Pathol. 2015 Feb;39(2):169-78
pubmed: 25517949
Eur J Cancer. 2014 Jun;50(9):1610-6
pubmed: 24703897
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
J Clin Pathol. 2016 Oct;69(10):852-7
pubmed: 26926101
Prostate. 2015 Feb 15;75(3):225-32
pubmed: 25307858
Histopathology. 2013 Oct;63(4):574-9
pubmed: 23931616